Shilpa is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $2.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Shilpa's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Otezla | Amgen | Generic | 2028 | FDA-approved Apr 2023 | $2.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Shilpa's share of it.